Company intelligence / Profile preview

Endogena Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

Endogena Therapeutics has advanced its lead program EA‑2353 into Phase 1/2 clinical trials for retinitis pigmentosa, with Fast Track designation from the FDA. Early data show preliminary evidence of efficacy. The company also received IND clearance from the FDA to begin clinical investigation of EA‑2351 in geographic atrophy secondary to AMD. Additional programs are in earlier stages targeting dry AMD, idiopathic pulmonary fibrosis, and hematopoietic recovery.

Therapeutic areas: OphthalmologyHematologyPulmonology
Modalities: Small molecules (selective regulation of endogenous adult stem and progenitor cells)
Industry: Biotech

Drug pipeline

3 assets

EA-2351

Unknown

2 more assets in the full pipeline.

Partnerships

JLABS Toronto (Johnson & Johnson Innovation incubator site hosting R&D facility)

Beyond the preview

Go deeper on Endogena Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endogena Therapeutics.